Press release - 15/11/2023 Nanoparticles for optimized cancer therapy Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.
Press release - 17/10/2023 BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.
Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.
Press release - 21/09/2023 Mutation-specific peptide vaccine against midline gliomas used in patients for the first time Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.
Press release - 13/07/2023 Intelligent rubber materials Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…
Expert interview - 05/07/2023 Every tenth of a degree matters when it comes to mitigating the consequences of global warming: sustainability measures in the laboratory The life sciences sector consumes huge quantities of energy and resources. This needs to change and we have to think differently. But how and where can sustainability measures be sensibly applied in the laboratory without compromising the quality of research results? Dr. Kerstin Hermuth-Kleinschmidt, owner of NIUB-Nachhaltigkeitsberatung, a company from Freiburg that focuses on sustainability in life sciences, tells BIOPRO how this can be done.
Press release - 03/07/2023 Skin rejuvenation for cancer prevention: DKFZ and Beiersdorf establish Joint Innovation Lab Rejuvenating skin and preventing skin cancer: That is the vision of the scientists at the new Joint Innovation Lab, which Beiersdorf and the German Cancer Research Center (DKFZ) founded on July 1, 2023. In the jointly operated lab, researchers are taking a close look at the "epigenetic clock" of skin cells with the aim of turning back biological aging and thus also reducing the risk of skin cancer.
Press release - 20/06/2023 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance in glioblastoma. A first data readout is expected in the second half of 2024.
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.
Press release - 08/05/2023 CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates. Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains.
Press release - 04/05/2023 Gamma delta T cells can fight aggressive breast cancer Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer with limited treatment options. Tumor growth and relapse of TNBC are driven by breast cancer stem cells, and improved therapies that can eliminate those hardy cells are urgently needed. Researchers from the University of Frieburg discovered that coordinated differentiation and changes in the metabolism of breast cancer stem cells make them invisible for…